“Translating the Pharmaceutical Legislation into Access & Affordability”
The 2022 Biosimilar medicines conference BIOS22 will take place in Brussels, Belgium on 6th & 7th October.
During this in-person event, speakers and panellists will explore how to turn the Pharmaceutical Strategy aim to ensure better access and affordability into concrete biosimilar medicine policy measures.
Recognising the prominent role of biosimilar medicines in delivering access to life-changing biological therapies, the ongoing dialogue on cancer and other non-communicable diseases is pointing towards greater value for healthcare systems, enabling progress towards integrated care for patients. Throughout the conference, debate and exchanges, as well as the presentation of examples and current practices, will foster ideas and data sharing.
The aim of this event is to multiply perspectives on existing challenges and future opportunities for biosimilar medicines policy to drive efficiency and contribute to the transformation of healthcare systems, and to inform the revision of the Pharmaceutical legislation.
Join us and have your say!
As a participant in this event, you will
- interact openly with thought leadersin the field
- engage in vibrant discussions with the full spectrum of healthcare stakeholders, policy makers and industry
- deepen your knowledge on the latest regulatory and scientific hot topics
- comprehend the impact that upcoming policy frameworkswill have on access to standards of care and competition in the biologics market
- broaden your understanding of complex market access and procurement features
- factor in international developmentswhen considering the longer-term perspective
- access actionable takeaways and good practices from experts in their fields with relevance to your daily work
We look forward to welcoming you to our event in Brussels!
In the meantime, please take a look at the April BIOS22 webinar “Biosimilar medicines: Changing patient pathways, Changing outcomes” during which we discussed biosimilar medicines value for healthcare.